Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05661916 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects | PHASE1 | COMPLETED | 96 | — | — | Jan 16, 2023 | Sep 30, 2025 | Feb 17, 2026 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| ALN-TTRSC04 | EXPERIMENTAL | Participants will be administered a single dose of ALN-TTRSC04. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ALN-TTRSC04 | DRUG | ALN-TTRSC04 will be administered by subcutaneous (SC) injection. |
| Placebo | DRUG | Placebo will be administered by SC injection. |
Inclusion Criteria: * Body mass index (BMI) ≥18.0 kg/m\^2 and ≤30 kg/m\^2 assessed at Screening. Exclusion Criteria: * Has an estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73m\^2 at screening. * Has alanine aminotransferase (ALT), aspartate aminotransferase (AST) or direct bilirubin a...